Meningioma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:35 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Meningioma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Lutetium (177Lu) Oxodotreotide for Patients with Recurrent Meningioma Without Surgery or Radiotherapy Options https://clinicaltrials.eu/trial/study-of-lutetium-177lu-oxodotreotide-for-patients-with-recurrent-meningioma-without-surgery-or-radiotherapy-options/ Wed, 29 Apr 2026 15:02:11 +0000 https://clinicaltrials.eu/trial/study-of-lutetium-177lu-oxodotreotide-for-patients-with-recurrent-meningioma-without-surgery-or-radiotherapy-options/ This clinical trial is focused on studying a condition known as recurrent meningioma, which is a type of brain tumor that has returned after treatment and cannot be treated with surgery or radiotherapy. The study is investigating the use of a treatment called [177Lu]Lu-DOTATATE, also known as Lutathera, to see if it can effectively reduce the size of these tumors. Lutathera is a solution that is given through an IV infusion, which means it is administered directly into the bloodstream through a vein.

The purpose of this study is to determine if Lutathera can provide enough benefit to justify further research. Participants in the study will receive either Lutathera or a placebo. The study will monitor the participants over a period to see how the treatment affects the tumor’s growth and the patient’s overall health. The study will also look at how the treatment impacts the patient’s quality of life, including aspects like cognitive and social functioning, as well as fatigue levels.

Throughout the study, participants will undergo regular MRI scans to assess the tumor’s response to the treatment. The study will also evaluate the safety and tolerability of Lutathera, ensuring that any side effects are carefully monitored. The ultimate goal is to see if Lutathera can help patients live longer without the tumor growing, which is referred to as progression-free survival. This study is an important step in exploring new treatment options for those with recurrent meningioma.

]]>